Drug
Fidaxomicin
Fidaxomicin: highest development phase Post-Market, developed by Astellas, Merck. 2 trial records tracked on RxWires.
- Highest phase
- Post-Market
- Developer
- Astellas, Merck
Trials
| Drug | Phase | Indication |
|---|---|---|
| Fidaxomicin NCT02692651 | Post-Market | Clostridium Difficile Infection (CDI) |
| fidaxomicin NCT02437591 | Post-Market | Inflammatory Bowel Disease (IBD) |
Latest
No recent events.
Follow Fidaxomicin on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.